Lead Product(s): DSP502
Therapeutic Area: Oncology Product Name: DSP502
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Kahr Medical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 02, 2021
Under the terms of the agreement, Samsung Biologics will provide its end-to-end cell line development and clinical drug substance and drug product manufacturing services as well as IND filling support for KAHR’s drug candidate DSP502, a TIGITxPD1 fusion protein.